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WELCOME
This year’s Children’s Mercy Cancer Center Annual Report focuses on tumors that
arise in the kidney and illustrates three important areas of focus that a childhood
cancer center must possess in this new age of medicine.
First, four of the five tumors that make up the vast majority of childhood kidney
cancer rarely, if ever, occur in adults. These are uniquely childhood cancers. The
fifth type of cancer that occasionally is seen in older children is the primary kidney
tumor in adults, yet itself is a unique subtype less frequently seen in adults. Few
circumstances of tumors arising from an organ in our bodies illustrate better the
dramatic difference between childhood and adult cancers.
Second, this difference emphasizes the need to have the expertise in childhood
cancer readily present as closely coordinated multispecialty care between the
pediatric oncologists and the many associated pediatric subspecialists, including
surgeons, radiologists, radiation therapists, pathologists and nephrologists, just to
name a few, who are experienced in treating childhood cancer.

“

Cancer, we now

know, is a disease
of the genes.
In few other
human diseases
is it so critical
to have the most

advanced genomic

”

capabilities
readily available.

It is so critical that these disciplines be present in a child’s multidisciplinary
team. This team approach provides these patients with the best opportunity
for a successful outcome, defined as not only a cure for the child’s cancer, but
a treatment approach that maximizes the child’s quality of life after cancer, life
intended to last at least another 80-90 years.
Approaching the child with this belief in mind has such great ramifications for
the child and family. Ensuring that in the years that follow, specific to the cancer
and its therapy, are monitored closely by experts in the long-term surveillance of
childhood cancers ensures the child’s ability to not only survive their cancer, but to
thrive, living life to the fullest.
Third, and finally, our brief dive into the world of childhood kidney tumors further
illustrates the rapid incorporation of cancer genomics and host genomics for
diagnostic improvements, prognostic and therapeutic improvements, and
family predisposition determination and monitoring. Cancer, we now know, is
a disease of the genes. In few other human diseases is it so critical to have the
most advanced genomic capabilities readily available. Incorporating these three
critical elements – pediatric focus and expertise, acute and long-term vision, and
advanced genomic expertise – children with cancer of the kidneys have seen
tremendous advances in their cure and their ability to live full and happy lives for
years to come.
We are excited to show you in the pages that follow that these critical elements
of care and discovery are here at Children’s Mercy, and are provided daily to our
children and their families who place their faith in us.

Alan S. Gamis, MD, MPH
Associate Division Director, Section of Oncology;
Professor of Pediatrics, University of Missouri-Kansas City School of Medicine;
Clinical Professor of Pediatrics, University of Kansas School of Medicine
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CANCER REGISTRY REVIEW
2019
The Cancer Registry at Children’s Mercy Kansas City plays a vital part in the
surveillance of cancer in our pediatric population. The Cancer Registry is a
HIPAA-compliant confidential database comprised of malignant cancers,
benign brain tumors and other specified benign tumors. The database is
operated under the guidance of the Cancer Care Committee. Data collected,
which includes diagnosis, treatment, recurrence and survival, is standardized
for state and national comparisons.
Following each patient’s cancer status is a very important part of Cancer
Registry data collection. Knowing outcomes of each cancer patient can assist
care providers with determining best treatment methods and long-term effects
of cancer treatment. Therefore, follow-up letters inquiring about a patient’s
cancer status are sent out yearly to patients not seen in our facility. Parents
and older patients are encouraged to contact the registry by secure email at
cancerregistry@cmh.edu to discuss follow-up.
During 2019, the Cancer Registry added 211 patients to the database. Of these
patients, there were 180 patients who were diagnosed with malignancies and
benign central nervous system tumors. There were 31 patients added to the
registry as having benign reportable conditions. These conditions are collected
at the request of the Cancer Care Committee for surveillance purposes and are
not required to be reported outside our facility. Please see the frequency by
diagnosis chart for a breakdown of cancers.

FREQUENCY OF DIAGNOSIS BY DISEASE TYPE - 2019 PATIENTS
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RENAL TUMORS DIAGNOSED 2010-2020*

WILMS PATIENTS BY STAGE DIAGNOSED
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* Mesoblastic nephroma is considered a benign diagnosis for the purpose of tumor

registries; thus it is not included in these diagnoses for our annual report. It should still be
considered as a possible diagnosis in children less than 1 year of age with a renal mass.
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RENAL TUMORS
The overarching story of the fight against
pediatric cancer over the last 60 years has
been one of frequent triumphs against
common cancers, combined with significant
though not uniform progress against other
malignancies, while still other diseases have
remained stubbornly resistant to conventional
therapeutic options. Along the way, much
has also been learned about the important
burdens borne by survivors of childhood cancer and the need to
mitigate those burdens by reducing treatment intensity where
possible. Perhaps in no group of childhood cancers is this story
better illustrated than in the significant progress and remaining
challenges in treating childhood and adolescent renal tumors.
Approximately 7% of childhood and adolescent malignancies
arise from the kidney and include Wilms tumor (also known as
nephroblastoma), renal cell carcinoma, clear-cell sarcoma of the
kidney, malignant rhabdoid tumor, and congenital mesoblastic
nephroma. The vast majority of pediatric renal tumors are
Wilms tumor, though congenital mesoblastic nephroma is more
common in the first month of life and renal cell carcinoma
becomes more common in older adolescents. Clear-cell sarcoma
of the kidney and malignant rhabdoid tumor remain rare entities,
but continue to pose important challenges, especially when
advanced or metastatic at diagnosis.

Wilms Tumor
First definitively described by Dr.
Max Wilms in 1899, Wilms tumor
overall stands as one of the
great success stories in pediatric
oncology. Improvements in surgical
techniques, utilization of radiation
therapy, and the use of risk-adapted
chemotherapy has led to survival
rates above 90% for the majority of
Wilms tumor patients. About 650
new cases are diagnosed in the
United States each year, with the
most common presentation being
an abdominal mass which may or
may not be painful. Microscopic or
gross hematuria can often be seen,
and hypertension occurs in over 25%
of patients. Occasionally, the tumor
can spread through the renal vein,
into the inferior vena cava, and even
into the right atrium. Spread can also
occur to lymph nodes, lungs, liver, or
(rarely) bone, bone marrow, or the
brain.
An ultrasound is often the first
imaging study obtained (often by
a referring provider), and definitive
work-up consists of a CT of the
abdomen to further define the mass
and to examine whether vascular
invasion has occurred. A CT of the
chest is also necessary to evaluate
for pulmonary metastatic disease.
Evaluation of blood pressure
is imperative, and aggressive
management (if needed) is indicated.
Initial laboratory work includes a
complete blood count (as microscopic
hematuria can lead to iron deficiency
anemia), serum chemistries
(including renal function tests), liver
function tests, and coagulation
assays.
In the United States and Canada,
initial therapy consists of radical
nephrectomy with adequate lymph
node sampling (not sampling
or under-sampling the regional
lymph nodes has been associated
with worse survival, likely due
to under-staging of the patient).

Although contraindications to
upfront nephrectomy exist (including
tumor thrombus in the IVC or bulky
pulmonary metastatic disease
making anesthesia unsafe), the
majority of renal tumors can be
safely resected prior to any systemic
therapy, allowing for complete and
accurate diagnosis, staging and
pathologic evaluation. Treatment,
including chemotherapy and possibly
radiation therapy, then proceeds
according to the patient’s stage,
histology type, and several genetic
and molecular factors. Combinations
of vincristine and dactinomycin
form the backbone of Wilms tumor
chemotherapy, with the addition of
other agents (including doxorubicin,
cyclophosphamide, etoposide, and
carboplatin) for more advanced or
metastatic disease, for those with
anaplastic histology, or for those
with loss of genetic material (loss of
heterozygosity) at specific locations
on chromosomes 1p and 16q.
Radiation therapy is necessary to the
local tumor bed for those with stage
III disease, as well as to any sites of
metastatic disease. Fortunately, if
patients with metastases only to the
lungs have a complete radiographic
response in the lungs after six weeks
of chemotherapy, lung radiation can
safely be avoided in most cases.
An important consideration in
the work-up and management
of children with Wilms tumor is
determining whether an underlying
genetic syndrome is present. Up to
10% of Wilms tumor patients have an
underlying syndrome such as WAGR,
Beckwith-Wiedemann, or DenysDrash syndromes which predispose
them not just to unilateral Wilms
tumor, but also to bilateral disease
(which can be present at diagnosis
in 5-10% of all Wilms tumor patients).
For these patients, the therapeutic
paradigm shifts somewhat based
on recently published data from
the Children’s Oncology Group (or
COG, the largest pediatric oncology

consortium in the United States
and Canada), with pre-operative
chemotherapy utilized to facilitate
removal of the tumors while sparing
as much healthy renal tissue as
possible.
Despite the general success in
curing Wilms tumor, important
questions still remain. Many patients
with low-stage disease and a lack
of poor biologic risk factors can
likely be spared exposure to either
anthracycline chemotherapy (with
the associated long-term risk for
cardiac dysfunction) and/or radiation
therapy while maintaining excellent
cure rates. Identifying how to
safely decrease therapy intensity is
important for minimizing the longterm health burdens for Wilms tumor
survivors. Additionally, in the last
decade, gain of genetic material at a
specific location on chromosome 1q
has been found to be present in up to
30% of Wilms tumors and is strongly
associated with poorer outcomes
overall. Questions remain about
how best to use this information
to augment therapy in patients
with 1q gain. Unacceptably low
outcomes persist for patients with
anaplastic histology Wilms tumor
and advanced or metastatic disease,
despite aggressive chemotherapy
and radiation therapy. How best
to increase the cure rates in these
patients continues to be debated.
Similarly, outcomes for patients with
relapsed Wilms tumor remain poor.
Over the next two to three years,
open clinical trials from the Children’s
Oncology Group (COG) will attempt to
answer these questions by improving
risk stratification techniques to allow
safe decreases in therapy for some
and vital therapy augmentation for
others, while seeking to improve the
outcomes of anaplastic and relapsed
Wilms tumor by incorporating novel
chemotherapy agents into historically
successful therapy backbones. The
next decade of Wilms tumor therapy
developments will be exciting!
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Clear-Cell Sarcoma
of the Kidney

Renal Cell Carcinoma
Renal cell carcinoma, though uncommon in children less than 15 years old,
still accounts for over 5% of pediatric and adolescent renal malignancies and
is therefore the second most common renal cancer in pediatrics. Work-up,
staging, and treatment of pediatric renal cell carcinoma has historically relied
on the application of adult renal cell carcinoma recommendations to children
and adolescents. It is only the last 15 years that the uniqueness of pediatric
renal cell carcinoma has become more apparent.
It is now clear that there are significant histologic and biologic differences
between pediatric and adult renal cell carcinoma. In particular, the most
common type in pediatrics (“translocation-associated renal cell carcinoma”)
is characterized by a genetic fusion involving the TFE3 gene on chromosome
Xp11.2 with one of many possible partners. Additionally, about 25% of
pediatric renal cell carcinomas do not clearly fit into the clear cell or papillary
subtypes that comprise the majority of adult renal cell carcinoma.
These and other biological insights are leading to questions about the
applicability of adult renal cell carcinoma treatment recommendations to
pediatric patients. Historically, treatment has consisted of partial or radical
nephrectomy with lymph node dissection, followed by close observation
for those with low-stage disease. Higher stage or metastatic disease has
been treated by targeting vascular endothelial growth factor receptor,
or VEGF-R (for example, with bevacizumab or sunitinib) or mammalian
target of rapamycin, or mTOR (for example, with sirolimus or temsirolimus).
Unfortunately, only retrospective reports have been published to demonstrate
how effective this approach has been.
Recently, however, collaboration with adult oncology cooperatives has led to
the opening of the first prospective, randomized trial for pediatric and adult
renal cell carcinoma, with the goal of establishing optimal up-front therapy for
advanced stage, metastatic, or recurrent translocation-associated renal cell
carcinoma (as noted, the most common subtype in pediatrics). While pediatric
renal cell carcinoma has been challenging in the past, the future definitely
looks promising.

Clear cell sarcoma of the kidney
(CCSK) accounts for about 5% of
pediatric renal cancers, or about 20
new cases per year in the United
States. Historically, it has had a
significantly higher rate of relapse
than favorable histology Wilms
tumor and has required more
intensive therapy. CCSK also has
a higher rate of metastatic spread
to the brain and to the bones than
does Wilms tumor, so brain MRI and
bone scan or PET/CT are important
additional parts of the work-up.
The staging and surgical approach
are the same as for Wilms tumor,
but diagnosis can be much more
challenging, as a number of
histologic variants have been
reported. Once the diagnosis is
made, though, chemotherapy
and radiation therapy are both
required for a cure. Chemotherapy
agents used include vincristine,
dactinomycin, doxorubicin,
cyclophosphamide and etoposide
in varying combinations.
Although cure rates are good
for stage I and II CCSK, stage III
patients have somewhat lower
expected outcomes (73% 5-year
event-free survival), and stage IV
patients have a dismal prognosis
(29% 5-year event-free survival on
the most recently published clinical
trial). Small numbers make studying
this disease challenging, but clearly
more work needs to occur to
improve outcomes for stage III and
stage IV CCSK patients.

Malignant Rhabdoid Tumor
Malignant rhabdoid tumor can
occur in many places in the body,
but the kidney (rhabdoid tumor of
the kidney) and the brain (where it is
known as atypical teratoid/rhabdoid
tumor) are the most common
locations. Malignant rhabdoid
tumors in all locations share a
common genetic aberration—loss
of function of the SMARCB1 gene
(though a small percentage instead
show loss of the related gene
SMARCA4).
This highly malignant tumor is
thankfully rare, but unfortunately,
about two-thirds of patients present
with advanced or metastatic
disease. Metastasis can be present
in the lungs, lymph nodes, soft
tissues, bone and brain, requiring
a brain MRI and bone scan or PET/
CT to be obtained as part of staging.

Complete surgical resection and
radiation are both necessary for
treatment of the primary tumor. The
addition of extremely aggressive
chemotherapy has yielded good
cure rates in the small percentage
of patients who present with stage
I or II disease. Unfortunately, cure
rates for stage III or IV disease are
dismal (stage IV patients had a fouryear event-free survival rate of only
about 11% on the most recent clinical
trial). A novel medication targeting
the molecular pathway, which is
activated by loss of SMARCB1, has
shown some promise at perhaps
improving these cure rates, but
clearly this is a cancer that has
proven quite resistant to traditional
therapies. Further prospective
clinical trials are needed to identify
better treatment strategies.

Summary
The battle against pediatric cancer
generally, and pediatric renal
cancer in particular, is slowly being
won, step-by-step, study-by-study,
patient-by-patient. Though much
work still lies ahead of us, this
story is worth being told, which is
why we have dedicated this issue
of Children’s Mercy Cancer Center
Annual Report to the fight against
pediatric renal tumors and the
inspiring patients, families and
professionals on the front lines.

Congenital
Mesoblastic
Nephroma
Congenital mesoblastic nephroma
accounts for about 5% of pediatric
renal cancers, and more than 90%
of cases are diagnosed within
the first year of life (and often
prenatally). It only rarely occurs
beyond 2 years of age. It can
be divided into three histologic
groups—classic, cellular and mixed.
Cellular congenital mesoblastic
nephroma frequently harbors a
genetic fusion between the ETV6
and NTRK3 genes which appears to
confer more aggressive behavior.
Nephrectomy is generally all
that is required for treatment of
classic, mixed, or stage I or II
cellular congenital mesoblastic
nephroma. Patients with stage III
cellular congenital mesoblastic
nephroma may benefit from
adjuvant chemotherapy, but
exciting new agents targeting NTRK
fusions (including NTRK3-ETV6) are
increasingly being studied, with one
drug now commercially available.
These agents hold the promise of
extremely effective treatment with
significantly reduced side effects for
this rare group of patients.
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the CHAMP
How a Little Boy
Defied Big Odds

“Hey mom! You know what 3 + 5 is?” asks inquisitive
6-year-old Chase Jackman.
“No Chase. What is it?” responds his mom, La Daya
Gordon.
“It’s 8!” Chase answers.
“Chase loves to count!” La Daya says, smiling. “And he
loves to play games. Connect 4. Jenga. PlayStation.
He’s a goofy, fun-loving kid who gives me like 1,000
hugs a day.”
But at just 7 months old, La Daya wasn’t sure her baby
would live long enough to give her those hugs, or learn
to count, or play any games. He was gravely ill, but no
one knew it until La Daya noticed his belly looked like it
was growing larger and larger.
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“I didn’t know what was going on,
so I took Chase to the Emergency
Department at the Children’s Mercy
Adele Hall Campus. He had been
constipated, so I thought that might
have something to do with it,” she
said.

Doctors weren’t sure what was
going on either.
“Initially, Chase was seen in the
emergency room and was found to
have signs of respiratory distress
and lymphangioma, a benign
lymphatic growth,” explained
Lindsey Fricke, RN, MSN, FNP-BC,
Nurse Practitioner.
Several days later, La Daya brought
Chase back to the emergency room.
His belly was even larger, and he
was sicker.
“Chase wasn’t a very big baby, but
he looked like he had a basketball in
his belly,” La Daya said.
Additional imaging confirmed
findings consistent with
lymphangioma, and Chase was
admitted to the pediatric intensive
care unit (PICU) to begin treatment
with sclerotherapy and medications.
While there, Chase developed a
serious condition called abdominal
compartment syndrome, and
doctors operated, opening his

abdomen to release the pressure
building up inside, and leaving his
abdomen open to heal.
“That day, doctors gave Chase 72
hours to live,” La Daya said. “We
probably had 100 family members
come to the
hospital to support
Chase through
surgery. We took
over the entire
waiting room.”
Though Chase
survived the
surgery, he was
intubated and
in the PICU on a
ventilator. In the
coming days,
doctors continued
therapy to shrink
the softball-sized
tumor they’d
found, but they still weren’t sure of
the source of the problem.

Troubling
Diagnosis
Three weeks later when Shawn St.
Peter, MD,
pediatric
surgeon and
Children’s
Mercy
Surgeonin-Chief,
was closing
Chase’s
abdomen, he
noticed some
suspicious
tissue that he
collected and
sent to the
lab.
The lab
diagnosed the tissue as a
cancerous tumor, and Chase started
chemotherapy treatment. But the
origin of the cancer remained a
mystery.

About one month into treatment, an
MRI showed the mass was getting
smaller, and it looked like it had
originated in the kidney.
“Because his pathology wasn’t
definitive, the tumor was sent
for additional analysis,” Lindsey
explained. Results determined
Chase’s cancer was an aggressive
tumor called cellular congenital
mesoblastic nephroma, which
accounts for about 5% of pediatric
kidney cancers. More than 90% of
cases are diagnosed within the first
year of life.
“Our oncologist said Chase was
probably born with the cancer, but it
often goes undetected because it’s
so rare,” La Daya said.

Aggressive
Tumor = Aggressive
Treatment
By now, Chase was nearly 1 ½
years old, and had spent months
on the hospital’s pediatric oncology
unit receiving additional cycles of
chemotherapy. He also had his left
kidney removed during his stay.

After completing treatment, the
cancer seemed to be gone.
But just a few weeks after returning
home, Chase’s stomach looked like

it was getting bigger again. La Daya
feared the worst, and she was right,
the cancer was back. It was bigger
than before—about the size of a
football—and it now involved his
abdominal cavity and spleen.
After surgery to remove the tumor
and his spleen, Chase’s oncologist
added several weeks of radiation
therapy to his treatment regimen,
along with the original chemotherapy
medications. Fortunately, Chase
responded well to the combination
therapy, but no one was quite sure
what to expect next.
While Chase was sick, La Daya said
she considered Children’s Mercy their
home. “If Chase was in the hospital, I
was in the hospital,” La Daya said. “I
didn’t want to leave his side.”
Chase even celebrated his first
birthday in Children’s Mercy. “We
had a huge party for him with the
doctors, nurses, family and friends,”
La Daya said.
Lindsey remembers the party well.
“Honestly, we weren’t sure there
would be a second birthday. He was
a very sick little boy.”
But Chase defied the odds. Today,
he’s been cancer-free for four years.
To be certain he stays healthy, he
sees Lindsey and Joel Thompson, MD,
pediatric oncologist, in the hospital’s
Outpatient Cancer Clinic, plus an
endocrinologist and a nephrologist.
At his last appointment, he graduated
to annual check-ups, and now he is
transitioning to the Survive and Thrive
Clinic—and that’s just what this young
cancer survivor is doing!

Follow Me!
During the months and months Chase
spent in Children’s Mercy, he earned
the nickname Chase the Champ,
winning the hearts of his doctors,
nurses and social media followers.
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“When Chase was in the hospital,
he would sit at the nurses’ station.
Everyone just loved him. He was
so resilient. He never complained,”
Lindsey said. “Even now, he doesn’t
complain, and his smile is just
infectious.”
While hospitalized, Chase became
a bit of a celebrity himself when
he got to meet several of the stars
involved in the Big Slick Celebrity
Weekend, an event that’s raised
millions of dollars to support the
Children’s Mercy Cancer Center.
When he was 3 years old, the
Make-a-Wish Foundation granted
Chase and his family his wish to
visit Disneyland. “We’ve kept that
tradition up, traveling about the
same time each year to a new
location,” La Daya said.

And, Chase has become a regular
at the annual Walk4Life event, which
also supports cancer patients. “Our
family and friends all wear their
Chase the Champ shirts and walk
every year,” La Daya said.
Yep! Chase is a popular guy. He’s
had more than 1,000 shares on
Facebook!

Lessons Learned
Throughout Chase’s journey, La
Daya said she’s come to appreciate
how fortunate they are that Chase is
now a healthy first-grader.
“At one point, doctors told me he
might not live 72 hours, and lots
of people have reached out to me
whose children haven’t survived. It’s
a relief to see how strong Chase is.
I’ve learned about strength and faith
along the way.
“And Chase thanks God he has no
more cancer,” La Daya said. “He has
scars on his belly, but to look at him,
you would never know all he’s been
through.
“The doctors and nurses at
Children’s Mercy were wonderful.
We loved everyone here, and still
keep in touch with some of the
nurses from 4 Henson on social
media,” she said.
La Daya, Chase and Chase’s father,
John Jackman, also would like
to thank the Hem/Onc team and
Lindsey. “We will never forget any of
you.”

PARTNERS IN THE DIAGNOSIS AND CARE
OF PATIENTS WITH RENAL TUMORS
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Urology

Molecular Genetics

The Pediatric Urology team is
dedicated to managing issues
related to the urinary tract and
genitalia. This includes the
management of both benign
and malignant renal tumors. Our
team works closely with other
subspecialties, such as anesthesia,
nephrology, oncology, pathology,
pediatric surgery and radiology,
to determine the ideal timing and
surgical approach for renal tumors.
Following the latest cancer treatment
protocols, we employ traditional
open surgeries or minimally invasive
approaches, such as cryoablation
and laparoscopic procedures.

The Molecular Genetics Laboratory is a specialty testing area of the Department
of Pathology and Laboratory Medicine. Together with the Genomic Medicine
Center, it helps provide comprehensive molecular genetic assessment for
patients with renal tumors. The Molecular Genetics Lab can perform testing on
a range of sample types such as blood specimens, buccal swabs, fresh tissue
and tissue that has been fixed in formalin, allowing testing to be done on a
wide variety of cases and for nearly all patients. It also offers a wide variety of
methodologies to look for genetic changes, including DNA fragment analysis,
multiplex ligation-dependent probe amplification, methylation testing and
Sanger sequencing. In doing so, it complements the Genomic Medicine Center,
which performs whole genome sequencing on paired tumor and normal
samples to look for genetic alterations. When present in the tumor (somatic),
such alterations can be important for diagnosis, prognosis and therapy. When
present in normal cells (germline), such genetic changes can point to cancer
predisposition and a heritable cancer syndrome, which has wider implications
for the patient and their family.

In children with conditions
predisposing them to recurrent
benign or malignant renal tumor
development, our team offers
nephron-sparing surgery. By only
removing the tumor and leaving
the normal kidney tissue, we can
preserve normal kidney function
without compromising the child’s
oncologic outcome. In children who
may be exposed to gonadotoxic
chemotherapy or radiation as part
of their treatment, our team offers
fertility preservation counseling for
males to help preserve future fertility.
We facilitate sperm banking for post
pubertal children, or testicular tissue
cryopreservation for prepubertal
children under a research protocol.
Our team has many years of
experience dealing with renal
tumors. Through collaboration and
a multidisciplinary approach, we
can successfully treat complex renal
tumors with excellent outcomes.

For patients with renal tumors, looking for both somatic and germline
alterations is critically important. Somatic changes in genes such as BCOR,
TP53 and VHL can confirm or rule out a diagnosis, give information about
prognosis, or point to a targeted therapy. Germline assessment is also
needed as a whole host of genetic syndromes are associated with increased
risk of developing renal tumors, such as Beckwith-Wiedemann syndrome,
WAGR syndrome, DICER1 syndrome, Von Hippel–Lindau syndrome, and
Rhabdoid tumor predisposition syndrome. Testing for all of these conditions
can be performed through the Molecular Genetics Laboratory and Genomic
Medicine Center and, together with the Cytogenetics Laboratory, it is done
comprehensively for all patients with renal tumors at Children’s Mercy.

Clinical Research
Clinical research is a major piece of the renal tumor success story. Children’s
Mercy, as a member of the Children’s Oncology Group, has been able to add
to the research by enrolling patients on both treatment and biology studies. A
group of dedicated research professionals within the Division of Hematology/
Oncology/BMT ensure that patients get presented opportunities to participate in
research that has been reviewed by our institutional ethics board. Studies may
be clinical trials offering new treatments, allowing their biological specimens to
be submitted for laboratory research, and even studies related to quality of life
and survivorship. Over the past four years, we have also been able to build a
local repository of renal tumor specimens through our on-site Tumor Bank which
includes Wilms tumor, renal cell carcinoma, and rhabdoid cancer of the kidney.

Pathology
Renal tumors are rare and comprise
approximately 7% of all malignant
pediatric tumors. This is a highly
heterogeneous group of tumors,
with each type of tumor having its
own specific diagnostic modalities,
prognosis, treatment, outcomes
and association with germline
predispositions. Histopathology is
the key to establishing the correct
diagnosis. Pathologists with expertise
in pediatric oncology are essential
for the diagnostic evaluation of these
rare tumors. Each renal tumor has
different histologic features. However,
there is considerable overlap in cell
type and histologic pattern of different
tumors, making the diagnosis difficult
to establish, if based on routine
histology alone. Therefore, there are
multiple ancillary techniques, such as
immunohistochemistry, cytogenetic
and molecular analysis, that are
crucial for the correct diagnosis,
prognosis and resulting appropriate
treatment. The role of the modern
pediatric pathologist is to evaluate all
conventional histopathology and all
ancillary techniques and synthesize
integrated diagnosis.
Wilms tumor comprises approximately
90% of pediatric renal tumors, with
the remaining types consisting of
clear cell sarcoma of the kidney,
malignant rhabdoid tumor of
the kidney, renal cell carcinoma,

congenital mesoblastic nephroma,
and other rare tumors. These tumor
spectra include those with low
malignant potential (congenital
mesoblastic nephroma) to highly
aggressive tumors (malignant
rhabdoid tumor of the kidney). Thus,
showing remarkable intra-tumor
histologic and genetic heterogeneity
and requiring different treatment.
Also, there is an increasing
number of pediatric renal tumors
demonstrating an association with
specific syndromes or diseases, such
as Wilms tumor association, with up
to 13 different syndromes including
Beckwith Wiedemann-syndrome
(loss of imprinting at 11p15), DenysDrash-syndrome (WT1 missense
mutations), Li–Fraumeni syndrome
(TP53 mutations), and WAGRsyndrome (Wilms tumor, Aniridia,
Genitourinary malformations, and
mental retardation; microdeletion
WT1 and PAX6). The malignant
rhabdoid tumor association with
Familial Rhabdoid Predisposition
syndrome (SMARCB1(INI1) mutation,
rarely SMARCA4 mutation), or SDHrenal cell carcinoma association with
germline SDH mutations associated
with Hereditary ParagangliomaPheochromocytoma Syndrome. These
highlight the importance of precise
pathologic tumor diagnosis, not only
for appropriate treatment, but also for
genetic counseling.

For histopathologic diagnosis, the
pathologist initially utilizes the pattern
approach. There are three major
histologic patterns that are the basis
for the differential diagnoses of
any tumor, including pediatric renal
tumors: an epithelial, a mesenchymal
and an undifferentiated pattern. In
Wilms tumors, all three patterns are
often present “triphasic pattern,” but
many Wilms tumors show only one
or two patterns or show the other
patterns only focally.
Therefore, extensive tumor
sampling is required, as well as
immunohistochemistry. The most
common pediatric renal tumors
with an epithelial pattern are Wilms
tumor which shows characteristic
strong nuclear staining for WT1, as
well as lack of staining for CK7, or
metanephric adenoma with strong
staining for BRAFV600E corresponding
to the BRAF mutation. Xp11.2
translocation renal cell carcinomas
(tRCCs) typically show large epithelioid
cells with copious amounts of
eosinophilic cytoplasm and a large
eosinophilic nucleolus and positive
nuclear TFE3 staining.
Papillary renal cell carcinoma shows
strong staining for CK7. The renal
tumor with the stromal pattern is
clear cell sarcoma of the kidney
showing up to nine histologic patterns
and specific strong nuclear staining

Triphasic Wilms tumor with primitive blastema, epithelioid component (tubules), and mesenchymal stromal component.
The cellular anaplasia (on the left), and positive WT-1 immunohistochemistry (right).
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for BCOR as well as CyclinD1. The
primitive, undifferentiated pattern
of presentation is most common
in pediatric renal tumors and may
be represented by undifferentiated
blastema of Wilms tumor, which
shows strong nuclear staining for INI1
as well as for WT1, and malignant
rhabdoid tumor with characteristic
large nuclei and loss of INI1 staining.
All described types and patterns of
pediatric renal tumors are complex
in diagnosis and prognosis. There
are large consortiums/registries of
these tumors in the U.S. and around
the world where clinical oncologists,
pathologists, cytogeneticists and
molecular pathologists study large
groups of these tumors to better
understand and diagnose these
lesions and develop new treatments.

Pediatric renal tumors vary by histological diagnosis, pathogenesis, genetics,
treatment and outcome. The cytogenetics laboratory processes the fresh renal
tumor specimens to gather as much information as possible for diagnostic
purposes and to subcategorize tumors by genomics which influence
therapeutic measures. The laboratory uses cell culture to grow the tumor cells
for chromosome examination, allowing a whole genome view of the tumor
and its specific genetic abnormalities (image 1). Samples processed with
fixative may be used for detection of diagnosing specific abnormalities using
fluorescence in-situ hybridization (FISH). DNA isolated from fresh and fixed
tumor may be used for examination by high-resolution SNP microarray of the
genome to detect abnormalities of copy number and loss of heterozygosity
(image 2), molecular examination using whole genome sequencing, or
molecular analysis of specific genes of interest. Appropriate intervention in
cancers starts with the correct diagnosis which includes the specific genetic
abnormalities that are unique to each individual tumor. As more knowledge
is gained regarding the genetics of tumors and correlation with response
to treatments, more specific individual therapeutic approaches are used to
improve patient outcomes.

Wilms tumor karyotype with an unbalanced translocation between
chromosomes 1 and 16 that results in gain of 1q and loss of 16q. This
genetic abnormality has prognostic and therapeutic significance.

Microarray analysis of the Wilms tumor shows loss of heterozygosity over 11p (purple),
gain of 1q (blue), loss of 16q (red) and other gains and losses over the genome. These
abnormalities impact prognosis.

Radiation Oncology
Radiation therapy continues to play
an important role in the treatment of
pediatric renal tumors, particularly
in the multidisciplinary management
of Wilms tumor. Successive National
Wilms Tumor Study (NWTS) trials
helped define the indications for
radiation therapy. The NWTS-1
and NWTS-2 studies employed an
age-adjusted dose regimen for
flank irradiation with an abdominal
relapse rate of 3-5% for group
II and III tumors with no doseresponse relationship observed.
The subsequent NWTS-3 trial was
pivotal in that it demonstrated that
radiation could be omitted for stage
II tumors when employing vincristine
and dactinomycin chemotherapy.
It also showed that the radiation
dose for Stage III favorable histology
could be reduced from 20 Gy to 10.8
Gy with the addition of doxorubicin
to the chemotherapy backbone of
vincristine and dactinomycin.

The timing of radiation seems to
be an important consideration
with these trials suggesting a
compromise in outcome with
delays in radiation beyond 10
days, particularly for unfavorable
histology. A subsequent analysis
of data from NWTS-3 and NWTS4 did not show inferior outcomes
with delays in radiation beyond 10
days. Nevertheless, it is generally
recommended to initiate radiation
therapy within 14 days of surgery.
Radiation therapy also plays
an important role in improving
cure rates in the setting of lung
metastases, where whole lung
irradiation is indicated. The most
recent COG trial recommends whole
lung irradiation based on response
to chemotherapy and LOH of 1p and
16q. The University of Kansas Health
System is our primary partner for
pediatric radiation therapy services,

with access to the most advanced
technology and radiation therapy
delivery techniques for the treatment
of our patient population. This
includes image-guided intensitymodulated radiation therapy (IMRT)
for whole lung irradiation, which
has been shown to provide superior
cardiac protection.
The University of Kansas Health
System is also currently constructing
a proton therapy facility, bringing
the latest state-of-the-art form of
radiation therapy to the region.
Proton therapy, with its superior
radiation dose distribution, promises
to significantly reduce radiation
dose to normal healthy tissues and
decrease the risk of late effects of
radiation therapy. We expect to start
treating children with proton therapy
in Kansas City as of December 2021.

Genetic Counseling
In some cases, pediatric cancers are associated with inherited mutations in
cancer-causing genes. There are several genes that are known to increase
the risk of cancer in children. Children with a strong family history of cancer
or a cancer type that is associated with a known cancer syndrome can
especially benefit from genetic counseling. Genetic counselors are trained
to elicit a detailed multi-generation family history and perform a risk
assessment, as well as explain the benefits, limitations, and implications of
genetic testing to both medical providers and families.
For example, a child with clear cell renal cell carcinoma should be evaluated
for the possibility of Von Hippel-Lindau syndrome, which can cause renal
tumors along with a wide variety of other tumors both in childhood and
adulthood. If a hereditary cancer syndrome is identified, at-risk relatives
including parents, siblings and extended family members can be tested for
the familial mutation. Individuals with hereditary cancer syndromes frequently
need increased lifelong surveillance that is tailored to their particular cancer risks. Genetic testing can identify which
individuals in a family need increased surveillance, which may be lifesaving.
The Children’s Mercy Division of Clinical Genetics has a genetic counselor who specializes in evaluating for pediatric
hereditary cancer syndromes and is regularly involved with families in which hereditary cancer is suspected. We also
have a Surveillance for Predisposition to Tumors (SPoT) Clinic that is designed to follow children who have tested positive
for a hereditary cancer syndrome and need individualized tumor surveillance. For more information about genetic
counseling and genetic testing for pediatric oncology patients, contact genetic counselor Caitlin Schwager, MS, CGC, or
the Division of Clinical Genetics.
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Family Care Team
Multidisciplinary care is integral to the overall outcomes and well-being of our patients. Outside of medically
directed care, patients and families have many other needs that are addressed by our Family Care Team (FaCT).
Regular FaCT collaboration ensures that all that physical, developmental, emotional, educational and spiritual needs
are met for our patients and families. The Family Care Team is available to assist from point of diagnosis through the
completion of treatment and beyond for patients with cancer.
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The Patient and Family Support
team consists of child life specialists,
a school teacher, music therapy,
and a patient activity assistant who
is also the handler of the facility
dog on staff that works on the
inpatient unit. Together, the team
works collaboratively to support the
psychosocial and developmental
needs of children and families.
Child life specialists are trained
professionals who help children
cope with the stress and uncertainty
of illness and hospitalization.

Child life specialists are child
development experts who work to
ensure life remains as normal as
possible for children in health care
settings through preparation, coping
and normalization. Preparation is
provided by child life specialists to

explain and teach patients about
medical procedures, coping skills
and other health care experiences.
Coping facilitation promotes
effective coping strategies to
help reduce anxiety and enhance
cooperation with the health care
event or diagnosis.
As advocates of family-centered
care, child life specialists work in
partnership with the medical team
to meet the unique emotional,
developmental and cultural needs
of each child. Hospital-based

school teachers establish a positive
learning climate of success for
students with chronic and serious
medical conditions, and coordinate
educational plans with home
schools. Music therapists provide

opportunities for self-expression
and development of positive coping
skills to promote increased comfort,
and to support developmental
growth. Music interventions are
designed after an assessment of
need and generally involve the use
of both live vocal and instrumental
music as well as technology. Goals
may include, but are not limited to
the reduction of pain or anxiety;
increased self-expression and
positive changes in mood; increased
physical strength and endurance;
greater relaxation; learning positive
coping strategies; and the support
of developmental skills. Patients are
encouraged to take an active role
in making music and learning how
to use music as a helpful and fun
tool. Patient activity coordinators
provide patient and family activities
and volunteer supervision.
Clinical social workers are master’slevel licensed professionals working
as part of the primary team to
provide comprehensive and
compassionate family-centered
care. Social workers understand
that any change in the child’s health
can alter a family’s life in many
ways and are trained to provide a
thorough assessment and address
the ongoing needs of the patients
and families. Social workers can
help with therapeutic support,
including adjustment to illness,
crisis intervention, development
of coping skills, family concerns,
end-of-life and bereavement; care
planning including education on
advance directives, school concerns,
legal issues, transition to adult
care, and end-of-life concerns;
and community/resource referrals

to assist with financial concerns,
transportation and lodging needs,
support and mental health referrals.
Every patient has an assigned
clinical social worker who follows
the patient and family through
diagnosis, treatment, relapse,
survivorship or bereavement.
The Parent to Parent Program
(PTP) continues to offer support
and comfort to all of the families
within our division through the
use of specially trained parent
volunteers and a clinical social
worker dedicated specifically to
PTP program management. There
are many services offered through
the PTP program including parent
volunteers available to share, listen
and support our current parents/
caregivers; two stocked parent
rooms that offer weekly dinners,
breakfasts, therapeutic and
educational activities and a safe
place to unwind while a child is an
inpatient; “care bags” for families
upon unexpected admissions to
help ease some burden of a hospital
stay; and new parent journals. The
Parent to Parent program also offers

an extensive
bereavement
follow-up
program that
supports
families for
approximately
13 months
after a child’s
death. We have
successfully
introduced
social media
into our
bereavement
follow-up
program and
have been
able to offer
additional
support in that
way. PTP has
worked closely
with a number
of local organizations, as well as
the Children’s Mercy Cancer Center,
and has established ongoing
philanthropic support of the parent
rooms to serve the increasing needs
of our inpatient families.
The Adolescent and Young Adult
(AYA) program is designed to
support patients receiving treatment
for cancer or blood disorders.
The team of providers includes a
clinical social worker and child life
specialist who work in collaboration
with other disciplines toward
the goal of improving the quality
of care for the AYA population.
Recent accomplishments include
the development of a teen unit
and teen room on our inpatient
floor, a formalized peer mentoring
program, additional programming
and education around fertility
preservation, and improvements to
the process around transitioning to
adult care. Ongoing projects include
the Hematology/Oncology Teen
Advisory Board, activities to promote
peer interaction, and ongoing
education and support.

There are two dedicated
psychologists to assist patients
and families with coping with
the diagnosis and treatment
of cancer. They are available
to meet with patients and their
families both while hospitalized
and when outpatients. In addition
to clinical therapeutic services,
the psychologists are also able
to complete neuropsychological
evaluations to assess any impact
of medical treatment on brain
functioning and to assist with school
re-integration and planning.
As a member of the Hem/Onc/
BMT team, the chaplain regularly
provides spiritual and emotional
support to patients and families
during the course of a child’s
illness, as end-of-life discussions
are necessary, at the time of death,
and beyond. Providing tailor-made
rituals for patients and families at
the time of significant events like
bone marrow transplant is another
way a chaplain provides support.
At the request of the family, the
chaplain can contact a family’s
own clergy person/spiritual leader.
For families who live outside of
the Kansas City area, again at the
request of the family, the chaplain
contacts a local leader from the
family’s faith tradition to provide
additional support. The chaplain
provides education about the
spiritual resources that are available
within the hospital, such as the
activities in the Lisa Barth Chapel
like Sunday worship, concerts and
celebrations from various faith
traditions. The chaplain participates
in team meetings. Providing support
to the staff is another important role
of the chaplain.
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The Survive & Thrive Program offers comprehensive medical and emotional care to childhood cancer
survivors who are at least two years off treatment and five years from the date of diagnosis. The program
offers five clinics per month with more than 350 survivors receiving care. Childhood cancer survivors are
at risk for health problems or late effects from their cancer and treatment. Late effects can be physical
or emotional and typically appear in the second decade of life. The development of late effects may be
influenced by the type of cancer, the treatment, age at diagnosis, and genetic predisposition. An estimated
95% of childhood cancer survivors will develop at least one late effect at some point during their life. Late
effects may be preventable or modifiable, which is why lifelong follow up is important for all survivors.
Examples of late effects that may occur in survivors include hearing loss, heart dysfunction, infertility, organ
dysfunction (i.e., restrictive or obstructive lung disease), endocrine dysfunction and development of a second
cancer. In the Survive & Thrive Clinic, survivors are monitored for development of late effects according to
the Children’s Oncology Group Long-term Follow-up Guidelines. The team ensures diagnostic tests and labs
are completed according to the guidelines and referrals are made to other specialists when necessary.
The Survive & Thrive team works closely with health care
providers in other specialties to ensure each survivor’s unique
health needs are met. Specialists the team works closely
with include Endocrinology, Cardiology and Developmental &
Behavioral Sciences.
In 2016, Children’s Mercy launched the Cardio-Oncology
Program to better meet the needs of cancer patients at
risk for developing cardiotoxicity (damage to the heart and
vascular system). The Cardio-Oncology program offers
specialized treatment that incorporates screenings by
pediatric cardiologists during cancer treatment and after for
survivors. Monitoring for and addressing cardiac concerns
early can reduce the risk of severe or life-threatening
heart problems. We also offer a collaborative clinic with
Endocrinology (EaST) clinic on a monthly basis to provide
coordinated care and decrease visits.
A visit to the Survive & Thrive Clinic includes a thorough
physical exam, recommendations for long-term follow-up care, education on late effects of cancer treatment
and how to maintain a healthy lifestyle. Assessments by a dietitian and social worker are included in the
survivorship clinic visit to ensure all needs of the survivor are met. In conjunction with the hospital-wide
Transition to Adulthood Program, preparation for transition to adult providers is incorporated into each visit
once survivors reach 15 years of age. The Survive & Thrive team works with each survivor to teach skills to
advocate for their health care needs and develop an individualized transition plan. At the time of transition,
the team works with the survivor, family and adult health care providers to ensure the transfer of care is
smooth for everyone involved in the process.

Bone and Soft Tissue Sarcoma Program
Sarcoma accounts for approximately 15% of all childhood cancers. Each year, Children’s Mercy treats approximately
15-20 children with bone or soft tissue tumors, the most common of which are osteosarcoma, Ewing sarcoma, and
rhabdomyosarcoma. The Bone and Soft Tissue Sarcoma Program at Children’s Mercy (in collaboration with the Sarcoma
Center at the University of Kansas Cancer Center) consists of highly-trained specialists in Pediatric Oncology, Orthopedic
Oncology, Radiation Oncology, Rehabilitative Medicine, Radiology, Pathology and Interventional Radiology who focus on
providing cutting-edge, family-centered sarcoma care from diagnosis through treatment and post-therapy monitoring.
We believe no child should have to leave the Kansas City area in order to receive elite, streamlined sarcoma care, and
providing such care is our daily priority. Additionally, with an expanding panel of collaborative research opportunities,
we are helping to identify the next generation of sarcoma therapies right here in Kansas City.
The Bone and Soft Tissue Sarcoma Program at Children’s Mercy is led by Joy Fulbright, MD, and Joel Thompson, MD. The
program consists of - Orthopedic Surgery (Howard Rosenthal, MD, and Kyle Sweeney, MD) Radiation Oncology (Ronny
Rotondo, MDCM, FRCPC), Rehabilitative Medicine (Kimberly Hartman, MD), Pediatric Oncology, Pathology, Interventional
Radiology and Radiology. Our goal is to provide seamless care coordination from radiation oncology to pathology and
orthopaedic surgery, with a multidisciplinary tumor board and enhanced collaborative research across disciplines.

Leukemia and Lymphoma

Neuro-Oncology Program

The Leukemia and Lymphoma Program at Children’s
Mercy is comprised of experts in the diagnosis and
management of hematologic malignancies in children
and young adults. Under the direction of Keith August,
MD, the Leukemia and Lymphoma Program is a
collaborative
effort dedicated
to delivering
state-of-theart clinical care
and to generate
innovative and
collaborative
research efforts.
Members are
multidisciplinary
and include
faculty from
the section of
oncology, bone marrow transplant, hematopathology,
cytogenetics and the cancer genomics program.
Comprehensive patient care meetings occur twice
monthly where every leukemia and lymphoma patient is
discussed among program members. Children’s Mercy
has a number of clinical trials available to ensure that
patients in Missouri and Kansas have access to exciting
new treatments that are rapidly transforming the care of
children with leukemia and lymphoma. Members of the
Leukemia and Lymphoma Program are actively involved
in the development of clinical trials for leukemia and
lymphoma on a national and international level through
the Children’s Oncology Group and other clinical research
consortiums.

The Children’s Mercy Cancer Center Neuro-Oncology
Program is a multidisciplinary program led by Kevin
Ginn, MD. The primary focus of the program is to provide
access to advanced cancer therapy and to improve
outcomes for children in the Kansas City region with
brain and spinal cord tumors. Central nervous system
tumors remain one of the leading causes of cancerrelated death and morbidity and these patients benefit
from the individualized care plans developed by multiple
subspecialists available at Children’s Mercy.
At Children’s Mercy, we treat approximately 50 new
patients a year and each patient is discussed at our
twice-monthly multidisciplinary tumor board. These tumor
boards allow in-depth discussion of new or established
patients ensuring thorough care planning to improve
patient care. Our involvement in National Consortiums
such as Beat Childhood Cancer and the Children’s
Oncology Group (COG) as well as pharmaceutic industry
relationships allows us to provide access to cuttingedge clinical trials for both new and relapsed patients.
Research collaborations through the Midwest Cancer
Alliance Partners and the University of Kansas Cancer
Center have resulted in research investigating new
therapies for glioblastoma and atypical teratoid rhabdoid
tumor which are two of the most devastating tumors
in pediatrics. The goal of the Neuro-Oncology Program
continues to be comprehensive care and cutting-edge
therapy provided close to home for every patient with a
central nervous system tumor that enters the doors of
Children’s Mercy.
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Experimental Therapeutics
The Experimental Therapeutics in Pediatric Cancer Program at Children’s Mercy
was founded in 2010 with a goal of providing access to early phase clinical
trials after relapse and/or progression has resulted in limited remaining
options for therapy. Over the years we have developed strong relationships
with consortiums and pharmaceutical companies increasing our ability to
have open trials available when they are needed. On average 25 clinical
trials are open at any time through our collaborations with Beat Childhood
Cancer, Children’s Oncology Group, Aflac Cancer Center at Emory Children’s
Hospital and industry partners. The Experimental Therapeutics team includes
three physicians, each with their own specific area of interest including neurooncology, solid tumors, blood cancers and cancer genomics (including ethnic
diversity and its relation to outcome/response). The team also includes a
nurse coordinator and three clinical research coordinators, who are vital to our
mission and help to maintain the trials and monitor study patients.
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In addition to patients from the Kansas City region, we have received a
number of outside referrals from centers in Wichita, St. Louis, Oklahoma,
Colorado, Iowa, Arkansas, Illinois and Texas. With the continued development
of the Children’s Mercy Research Institute and our strong relationship as a
consortium partner in the NCI-Designated University of Kansas Cancer Center,
we are poised to become a national leader in innovative cancer treatments for
children. Access to early phase clinical trials has made a significant difference
for children with cancer in Missouri, Kansas and the region.
Children’s Mercy Cancer Center was selected to join the Children’s Oncology
Group Pediatric Early Phase-Clinical Trial Network (PEP-CTN) as a non-core
member beginning in 2021. The PEP-CTN is the early phase clinical trial arm of
the Children’s Oncology Group and previously included only 21 core member
institutions. In the Fall of 2020, Children’s Oncology Group member institutions
were invited to apply as a non-core member and the PEP-CTN would choose
up to 20 sites based on infrastructure, experience and patient numbers. Given
our experience with consortium and industry-based early phase trials within
our Experimental Therapeutics in Oncology Program and the infrastructure in
place to run early phase clinical trials safely and effectively, Children’s Mercy
was invited to join this prestigious group of pediatric oncology centers. Our
involvement in the PEP-CTN provides the opportunity for regional children and
adolescents battling cancer to access these trials on the forefront of cancer
therapy research.

Spanish-Speaking Cancer Clinic
The Spanish-Speaking Cancer Clinic offers pediatric oncology services to
Hispanic patients and families who speak limited English. The team is dedicated
to providing quality medical care that recognizes Spanish language needs and
cultural differences related to health care.
The team is dedicated to better understanding the ethnic and genetic
differences in outcomes among Hispanic patients with leukemia. Ongoing
research in partnership with the genomics program focuses on the genetic
factors in these differences, which will help us provide better treatment
to patients. The program also provides trainee education to develop and
improve Spanish-language skills and promote cultural awareness in the
clinical setting.

Adolescent and Young
Adult Program
Children’s Mercy provides dedicated
services for adolescents and young
adults with cancer (age 13 to 22). The AYA
program is designed to support patients
receiving treatment for cancer or blood
disorders and specializes in providing
psychosocial support and connecting
patients with clinical trials through their
early 20s.
The team of providers includes a clinical
social worker and Child Life specialist
who work in collaboration with other
disciplines toward the goal of improving
the quality of care for the AYA population.
Recent accomplishments include the
development of a teen unit and teen
room on our inpatient floor; a formalized
peer mentoring program; additional
programming and education around
fertility preservation; and improvements
to the process around transitioning to
adult care. Ongoing projects include the
Hematology/Oncology Teen Advisory
Board; Teenapalooza events to promote
peer interaction; and ongoing education
and support.

Histiocytosis
Program
The Histiocytosis Program at Children’s
Mercy provides a comprehensive setting
for care of rare diseases. The experienced
team collaborates to treat conditions
such as Langerhans Cell Histiocytosis,
Hemophagocytic Lymphohistiocytosis,
sinus histiocytosis with massive
lymphadenopathy, and Erdheim-Chester
disease.
The program provides a team approach to
care that features collaborations between
multiple services when needed, including
the expertise of a pediatric hematologist/
oncologist, pediatric nurse practitioner, and
a pediatric social worker. The Histiocytosis
Program also collaborates with
pediatric orthopedic surgeons, pediatric
endocrinologists, pediatric dermatologists
and pediatric pathologists.
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Cancer Genomics
The Children’s Mercy Cancer Genomics Program brings together pediatric oncologists, molecular pathologists,
genomics research faculty, bioinformaticians, genetics counselors, and many more, with the primary goal to improve
survival through genomics sequencing. We are proud to offer comprehensive somatic (cancer cell) and germline (noncancer cell, potentially heritable) molecular testing to every child treated for cancer at Children’s Mercy. This allows our
team to better classify the molecular subtype and the risk of recurrence, and to tailor treatments for each individual
patient. In some cases, we may identify a genetic variant that predisposes to cancer and we can then offer genetic
counseling, testing to immediate family members and surveillance for children and adolescents identified to be at risk
of cancer. Surveillance identifies cancers at earlier stages and saves lives. In addition to clinical sequencing, our team is
actively leading genomics research projects in leukemia, lymphoma, solid tumors and brain tumors. We are exploring
the underlying biology driving childhood cancers and, through collaborative partnerships with the University of Kansas
Cancer Center, the National Cancer Institute, and other pediatric hospitals, we are committed to sharing our knowledge
and accelerating the pace of genomics discoveries, which benefits the scientific community, our patients and their families.

Liver Tumor Program
The liver cancer treatment team at Children’s Mercy
combines the medical and surgical expertise of the
Division of Hematology and Oncology with the Liver Care
Center. This program provides specialized services and
research for treating pediatric patients with malignant
liver tumors.
The program provides specialized treatment for pediatric
hepatoblastoma, the most common malignant liver
tumor in the United States. Once patients complete
treatment, the team continues to follow their progress
through a quarterly liver tumor clinic.

Stem Cell Transplant and
Cellular Therapies
The process of caring for a child who needs a transplant
is complex and requires the skills and expertise of
a team of specialists. Each year, the BMT Program
performs approximately 40 transplants for children and
adolescents up to age 21. Transplants are done to treat
varying forms and stages of cancers, immune disorders,
blood (hematologic) disorders, and metabolic disorders.
Our immunotherapy program offers new therapies to a
growing number of patients.

He’s a

TRIPP!

How Cancer Treatment
Saved This Fun-loving
5-year-old’s Life

At 5 years old, Tripp Chase loves to play with his toy cars,
dinosaurs and Legos. He’s a typical boy, except for one thing. He
was diagnosed with an aggressive form of Wilms tumor in 2019—
a kidney tumor that required the state-of-the-art cancer care
available at Children’s Mercy Kansas City.
Tripp’s cancer story began when he was just 3 years old. Jolynda
Chase, Tripp’s mom, said he had been a healthy child until one
night when he started crying and grabbing his stomach in pain.

of childhood kidney cancer called
Wilms tumor. What wasn’t common
was that it had already spread to
Tripp’s lymph nodes.
“About 650 cases of Wilms tumor are
diagnosed in the United States each
year,” explained Joel Thompson, MD,
pediatric oncologist with Children’s
Mercy and Tripp’s physician. “In most
cases, surgery is the initial treatment.”
Unfortunately, analysis of Tripp’s
tumor revealed more widespread,
aggressive anaplastic disease.
“Based on the pathology, from the
outset, we knew Tripp’s treatment
would be more challenging. He would
need both radiation and intense
chemotherapy for the best chance of
survival,” Dr. Thompson said.

Family Sacrifices

26

“He hadn’t had a bowel movement in
three days, so we thought he might
just be constipated,” Jolynda said. But
when Tripp’s doctor in Colby, Kan.,
X-rayed his abdomen, it looked like
he had an enlarged liver.
The next week at a follow-up
appointment, Tripp had an abdominal
ultrasound that confirmed he had a
large mass either on his right kidney
or liver. “Our doctor wanted Tripp to
have a CT scan, and referred us to
Children’s Mercy for the test,” Jolynda
said.
On Wednesday, July 17, 2019, Jolynda
and Tripp made the six-hour drive
from their Winona, Kan., home to
Kansas City. Later that day, Tripp’s
family learned the source of the
problem—he had a large tumor on
his right kidney, a tumor that needed
to be removed immediately.
Two days later, on Friday, July 19,
Tripp had surgery to take out his
right kidney and the tumor. A biopsy
confirmed Tripp had a common type

For Tripp’s family, there was no
question that he was in the right place
to get the care he needed, but it came
at a steep price.
“I had just given birth to Tripp’s baby
sister two months earlier,” Jolynda
said. Plus, Tripp has two older
brothers, ages 6 and 11. Jolynda
stayed in Kansas City to be at her
son’s side during treatment, while
Tripp’s father took care of the other
three children in Winona with the help
of family and friends.
“Tripp’s parents are the
calmest people ever,”
said Lindsey Fricke, RN,
MSN, FNP-BC, Nurse
Practitioner. “You never
would have known that
anything crazy was
happening in their lives.
I know this had to be
difficult for them, but they
took everything in stride.
I never heard Jolynda
complain.”
Dr. Thompson agreed
and said Tripp’s family
support was remarkable.

“If they were stressed, they never
let us see it, and I don’t think Tripp
sensed it either,” he said. “That
allowed us to focus on his treatment,
and help Tripp get better.”

Tough Therapy for a
Tough Tumor
Tripp’s treatment began just two
weeks after his right kidney was
removed. Dr. Thompson prescribed
radiation therapy and chemotherapy,
a powerful one-two punch reserved
for the most aggressive Wilms tumor
cases.
While chemotherapy was performed
at Children’s Mercy, Tripp’s radiation
therapy was delivered at the
University of Kansas Medical Center,
the hospital’s partner in radiation
oncology. In all, Tripp received 11
radiation treatments, and eight
months of chemotherapy.
“Tripp did well with the radiation
therapy, but the chemotherapy was
hard on him,” Jolynda said. Though
technically he was able to return
home between treatment cycles, he
often ended up back in the hospital
when he would spike a fever.
“This is an intense regimen of
chemotherapy, and there are side
effects,” Dr. Thompson said. “As

it wipes out the patient’s immune
system, they’re at higher risk for
infection, and that’s what happened
to Tripp.

Thompson said. “I knew if he could
tough this out, there was about a
75 to 80% chance that he would be
cured.”

“Toward the second half of his
chemotherapy treatments, Tripp
would get a fever about day eight
of every cycle. It was almost like
clockwork,” Dr. Thompson added.

Thriving After
Treatment

Jolynda knew if her son’s fever rose
above 100.5 degrees, it was an
emergency. “We tried to return home,

Though the cancer scare isn’t
completely behind Tripp, it’s now
been nine months since he finished
treatment, and he’s thriving!
“Tripp is back
in school and
loves being
with family and
friends, playing
with his brothers
and his baby
sister,” Jolynda
said. “We are all
glad to be back
home.”
“Tripp is a
fun-loving kid,”
Lindsey added.
“He’s always
playing with his
cars or attacking
me with his
dinosaurs at his
check-ups.”

but over the months, Tripp had to be
flown back to Kansas City 10 times.
The flight crew called him their little
frequent flyer,” Jolynda said.
Chemotherapy also took a toll on
Tripp’s appetite and digestive system.
Eventually he needed a feeding tube
to be sure he received adequate
nutrition. And, chemotherapy affected
the nerves in his legs, causing some
neuropathy and pain. But overall,
Tripp fought through the treatment
and its side effects.
“For his stage of diffuse anaplastic
Wilms tumor, this was pretty standard
treatment, but it is extremely intense,
and there can be a lot of side
effects, which Tripp experienced,” Dr.

Dr. Thompson said even when Tripp
was hospitalized and not feeling well,
he’d curl up in the chair beside his
bed, snuggling with his warm fleece
blanket, and playing peek-a-boo.
“Now that he’s healthy and on the
other side of treatment, wow, his
personality is out!” Dr. Thompson said.
“That’s so great to see.”
With treatment behind him, Tripp will
continue to see Dr. Thompson and
Lindsey regularly for the next five
years for follow-up appointments to
be certain the cancer doesn’t return,
and to monitor his kidney and heart
functions, both which could have
been impacted by the radiation and
chemotherapies.

“Tripp’s diagnosis was a big shock
for us. I never thought something like
this would happen to our family and
it was really hard to take. There were
a lot of stressful, sleepless nights,”
Jolynda admitted. “But we couldn’t
have asked for better doctors or
nurses than we had at Children’s
Mercy.”
For Dr. Thompson and Lindsey, Tripp
epitomizes the reason they care for
kids with cancer.
“It was heartbreaking to see Tripp
undergo the short-term pain and
suffering of his treatment, but I knew
there was a good chance that in the
long term, he could beat cancer,” Dr.
Thompson said.
“After Tripp’s last visit, as I was walking
out of the exam room, I thought to
myself, ‘This is why I do what I do,
because of how good Tripp feels and
looks.’ He’s now a normal 5-year-old
and on the other side of this.”
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CHAMPIONS FUELING CANCER CARE
AND RESEARCH

Hope Hero honoree, Arden,
was all smiles for the 9th
Annual Hope Gala led by
Braden’s Hope for Childhood
Cancer. The virtual event, held
on September 26, raised more
than $575,000 for pediatric
cancer research projects driven
by teams from Children’s Mercy,
KU Cancer Center, and the
Stowers Institute for Medical
Research.

BRADEN’S HOPE

The Children’s Mercy Cancer
Center Auxiliary hosted a virtual
trivia night to raise $6,600 in
support of the annual Holiday
Hero campaign and families
battling pediatric cancer and
blood disorders at Children’s
Mercy. The Cancer Center
Auxiliary also hosts their annual
Holiday Hero campaign, raising
more than $100,000 to support
patients and families battling
pediatric cancer and blood
disorders.

BIG SLICK

Big Slick hosts Rob Riggle,
Paul Rudd, Jason Sudeikis, Eric
Stonestreet and David Koechner
went online, from home, for
this year’s fundraising event
benefiting pediatric cancer
research at Children’s Mercy.

CANCER CENTER
AUXILIARY

In 2020, more than 300 champions invested in cancer care and research at
Children’s Mercy through creative events, heartwarming tributes, and more.
Our community of champions ensures that kids in Kansas City and across
the region have the best care possible, right here at Children’s Mercy.

The Long family enjoyed the
outdoors during the 5th Annual
Noah’s Crown Town 5K. The
virtual event, held on April 19th,
supported Noah’s Bandage
Project, a major supporter of
pediatric cancer research at
Children’s Mercy.

DREAM BIG DAY NOAH’S BANDAGE
PROJECT

Children’s Mercy Dream Big Day
was a virtual family-friendly
festival, celebration and walk
to rally our community around
finding answers and hope for
kids. More than 900 people and
70 teams came together virtually
to raise more than $227,000 and
help kids’ dreams – big or small
– become a reality.

BLACK & VEATCH
GOLF TOURNAMENT

Even though Black & Veatch had
to cancel their annual charity
tournament to benefit Children’s
Mercy due to COVID-19, the
company still showed their
commitment to the hospital with
a donation of 5,000 face masks
for staff at Children’s Mercy!
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The Black & Veatch Building, on the Children’s Mercy Adele Hall Campus in Kansas City, Mo.,
houses the Division of Hematology/Oncology/Blood and Marrow Transplant.

PHILANTHROPIC DONORS TO
THE CANCER CENTER IN 2019-2020
Thank you to the donors of $25K+ and donors that established
a planned gift:

Alex’s Lemonade
Stand Foundation

DeBruce Foundation

Louise and Tom Reichl

Ann and Matt Anthony

The Stanley H.
Durwood Foundation

Austie Strong
Foundation

Sarah and Scott
Ferguson

Victor E. and Caroline
E. Schutte Foundation
Trust E, David W.
Frantze and Bank of
America, N.A.

Alyssa and Steve
Barton

David and Geri Frantze

Lisa and Dolph Simons

Give Hope Back

Lisa and Arthur R.
Smith

Big Slick
Black & Veatch
Corporation
Braden’s Hope for
Childhood Cancer
James M. Burcalow
Children’s Mercy
Cancer Center
Auxiliary
The Jared Coones
Memorial Foundation

Shelly and George
Handy
Mike and Linda Hayes
and Hayes Drilling
Hug Your Kids
Foundation
Hyundai Hope on
Wheels
Mr. and Mrs. Henry J.
Massman IV

Curing Kids Cancer

Laura and Hatch
McCray

Roderick J. and Jo
Anne Cyr Foundation

Noah’s Bandage
Project

Linda and Paul
DeBruce

Sam Price Family
Foundation

Mary and Steve Soden
Victor E. Speas
Foundation, Bank of
America, N.A., Trustee
Vida Elizabeth
Thompson
C. W. Titus Foundation
Tour de BBQ, Inc.
Ann and Frank Uryasz
Christy and Bret
Wilson
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GROWING FOOTPRINT OF CANCER
RESEARCH
With the opening of the Children’s Mercy Research Institute (CMRI), the
footprint of Children’s Mercy research took a giant step forward. For the Cancer
Program, collaboration and the building of research infrastructures has been
developing over the last several years. Here are some of the researchers
building our program.
Doug Myers, MD, Immunotherapy Laboratory located in the CMRI
Lab Members: John Szarejkeo, PhD
Principal Collaborators: John Perry, PhD
Cancer focus: Immunotherapy of solid pediatric tumors with a focus on using chimeric
antigen receptor T-cells and tumor antigen-specific T-cells for treatment of neuroblastoma.

John Perry, PhD, Targeted Therapy Laboratory located in the CMRI
Lab Members: Jackie Nemechek, PhD; Fang Tao; Jennifer Pace; Kealan Schroeder, MPH;
and John Szarejko, PhD
Principal Collaborators: Doug Myers, MD; Todd Bradley, PhD; Scott Younger, PhD; Scott
Weir, PharmD, PhD (KU); Alan Gamis, MD; Erin Guest, MD; Chandni Dargan, MD; Bradley
Stockard, PharmD, PhD; and Sara McElroy, MD
Cancer focus: Targeted therapies for relapsed/refractory leukemia.
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Cancer Genomics Program led by Erin Guest, MD, Midhat Farooqi, MD,
PhD, and Tomi Pastinen, MD, PhD, located in the CMRI
Program Members: Byunggil Yoo, MS; Neil Miller; Maggie Gibson; and Emily Farrow, PhD
Key Collaborators: Sarah McDermott, MD; Linda Cooley, MD; Sultan Habeebu, MD; Mark
Hoffman, PhD; Amy Hont (CNMC); Holly Meany (CNMC); Catherine Bollard (CNMC); Jason
Wang (Cook Children’s); Dinesh Rakheja (Children’s Dallas); Keith August, MD; Tristan Flatt,
DO; Atif Ahmed, MD; and Elizabeth Gonzalez Dominguez, MD
Cancer focus: Genomics, TransCMRIptomics, and epigenomics of leukemias and solid
tumors.

Cancer Research Informatics and Data Science led by Mark Hoffman, PhD
Program members: Sierra Davis; Earl Glynn; and Janelle Noel-MacDonnell, PhD
Key Collaborators: Karen Lewing, MD; Nikki Wood, DO; and Doina Caragea, PhD (Kansas
State)
Cancer focus: Acute lymphoblastic leukemia.

Taeju Park, PhD, Brain Tumor Research Laboratory located in the CMRI
Lab members: Neka Large and Olivia Funk
Principal Collaborators: Tom Curran, PhD, FRS; Anuradha Roy, PhD (KU); Scott Weir, PhD
(KU); Frank Schoenen, PhD (KU); Justin Douglas, PhD (KU); David Johnson, PhD (KU); and
Kevin Ginn, MD
Cancer focus: Development of novel chemotherapy drugs to treat brain tumors, including
glioblastoma and diffuse midline glioma.

Tomoo Iwakuma, MD, PhD, Translational Laboratory Oncology Research
(TLOR) located in the CMRI
Lab Members: Alejandro Parrales, PhD; Atul Ranjan, PhD; Shigeto Nishikawa, MD, PhD;
Atsushi Kaida, DDS, PhD; Mohamed Alalem, MD, PhD; Elizabeth Thoenen; Hongyi Ren; and
Etsuko Iwakuma, NS
Principal Collaborators: Scott Weir (KUMC); Sufi Thomas (KUMC); Francisco Diaz (KUMC);
Shrikant Anant (KUMC); Anuradha Roy (KU); Frank Shoenen (KU); and John Karanicolas (Fox
Chase)
Cancer focus: p53, osteosarcoma, Ewing sarcoma, liver cancer, head and neck cancer,
lung cancer.

Glenson Samuel, MD, Godwin Lab at University of Kansas Cancer Center
Lab Members: Jennifer Crow, PhD, and Soumya Turaga, PhD
Principal Collaborators: Andrew Godwin, PhD (Principal Investigator-KU); Yong Zeng,
PhD (University of Florida); Joaquina Baranda, MD (KU); Kyle Jackson, MD, MPH (Indiana
University); Michael Merchant, PhD (University of Louisville); Genomic Medicine Center
(Children’s Mercy); and Mihaela Sardiu, PhD (Stowers Institute)
Cancer Focus: Predictive and prognostic biomarkers, liquid biopsies based on extracellular
vesicles, and therapeutics in Ewing Sarcoma; pediatric sarcomas.
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